Shares of Lincoln Pharmaceuticals traded steadily as the company announced its financial results for the second quarter of fiscal year 2025 (Q2 FY25), highlighting steady growth in revenue and profitability.
Key Financial Highlights for Q2 FY25:
- Revenue from Operations: Lincoln Pharmaceuticals reported a revenue of ₹161.21 crore for Q2 FY25, up by 3.4% year-over-year (YoY) from ₹155.99 crore in the same quarter last year. Quarter-over-quarter (QoQ), revenue grew by 9.4% from ₹147.28 crore in Q1 FY25.
- Total Income: The company’s total income, including other income, stood at ₹171.19 crore in Q2 FY25, reflecting a 4% YoY growth from ₹164.68 crore and an 8.6% QoQ increase from ₹157.69 crore in the previous quarter.
- Net Profit: Net profit for Q2 FY25 was ₹26.33 crore, marking a slight YoY decrease of 4.8% compared to ₹27.65 crore in Q2 FY24. However, on a QoQ basis, net profit grew by 11.2% from ₹23.67 crore in Q1 FY25.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Neither the author nor Business Upturn is liable for any losses arising from the use of this information.
